The unfolded protein response is responsible for the detection of misfolded proteins and the
coordination of their disposal and is necessary to maintain the cellular homoeostasis …

Abstract The PI3K/AKT pathway is constitutively active in hematologic malignancies,
providing proliferative and antiapoptotic signals and possibly contributing to drug resistance …

Acquired resistance toward apoptosis represents one of the hallmarks of human cancer and
a major cause of the inefficacy of most anticancer treatment regimens. Based on its ability to …

Multiple myeloma is a hematologic malignancy characterized by the proliferation of
neoplastic plasma cells in the bone marrow. Although the first-to-market proteasome …

Seventy-six FDA-approved oncology drugs and emerging therapeutics were evaluated in 25
multiple myeloma (MM) and 15 non-Hodgkin's lymphoma cell lines and in 113 primary MM …

Panobinostat, a pan-deacetylase inhibitor, represents a novel therapeutic option for cancer
diseases. Besides its ability to block histone deacetylases (HDACs) by promoting histone …

Multiple myeloma (MM) is a malignant disorder of differentiated B-cells for which standard
care involves the inhibition of the proteasome. All clinically used proteasome inhibitors …

The unfolded protein response (UPR) is an essential pathway for both normal and malignant
plasma cells to maintain endoplasmic reticulum (ER) homeostasis in response to the large …

The integration of novel agents into the treatment of multiple myeloma (MM) has shifted the
focus from an incurable disease to one that is chronic, with a realistic hope of someday …

Amplification and/or overexpression of the human epidermal growth factor 2 (HER2)
oncogene occurs in about 13–15% of invasive breast cancer and triggers breast cancer cell …